Somatrogon‑Ghla Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 24 mg/1.2 mL, 60 mg/1.2 mL

Reference Brands: Ngenla (USA)

Category: Critical Care

somatrogon‑ghla is available in injection (prefilled syringe) and strengths such as 24 mg/1.2 mL, 60 mg/1.2 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, somatrogon‑ghla is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

somatrogon‑ghla can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Somatrogon‑ghla, sold under the brand name Ngenla, is a long-acting human growth hormone analog used for the treatment of growth hormone deficiency in pediatric patients. It is a glycosylated protein constructed from human growth hormone with small sequences of human chorionic gonadotropin appended to both the N-terminal and C-terminal, which prolong its half-life and allows for once-weekly subcutaneous administration. Ngenla is indicated for children aged three years and older who experience growth failure due to insufficient secretion of endogenous growth hormone. By supplementing growth hormone levels, somatrogon‑ghla promotes normal growth and helps achieve height progression in children with growth hormone deficiency. The medication is provided as a prefilled subcutaneous pen available in strengths of 24 mg/1.2 mL and 60 mg/1.2 mL, enabling accurate dosing based on body weight. The most commonly reported side effects include injection site reactions, headache, and fever. Following treatment discontinuation, normal growth hormone activity resumes, and fertility or other hormone functions are not adversely affected. Ngenla has been developed to provide a convenient and effective therapy, reducing the frequency of injections compared to daily growth hormone therapies while maintaining efficacy.